Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002131 | 0.95 | HTR2A (0.54) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970884 | 0.90 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL26056043 | 0.88 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002187 | 0.86 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002101 | 0.85 | HTR2A (0.57) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002147 | 0.85 | HTR2A (0.52) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002071 | 0.84 | HTR2A (0.51) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970855 | 0.83 | HTR2A (0.61) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002138 | 0.82 | HTR2A (0.61) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002059 | 0.81 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | 2A BIOSCIENCES, INC. | 2025-11-20 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025030181-A1 | CRYSTALLINE POLYMORPHS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE (2C-B) | ARCADIA MEDICINE, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | KULEON LLC (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | KULEON LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | Kuleon, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024077203-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122320-A1 | POLYPODAL SEROTONERGIC COMPOUNDS AND PRODRUGS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022006186-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR2A 6/4885HTR2C 8/4885HTR2B 11/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR2C 2/4885HTR2B 7/4885 |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | HTR5A, PNMT, HTR6 | HTR2A 8/4885HTR2C 7/4885HTR2B 17/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR2C 2/4885HTR2B 7/4885 |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | HTR2A 11/4885HTR2C 3/4885HTR2B 23/4885 |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | HTR2A, HTR2C, HTR1A | HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885 |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR3B | HTR2A 2/4885HTR2C 1/4885HTR2B 4/4885 |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885 |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR3B | HTR2A 2/4885HTR2C 1/4885HTR2B 4/4885 |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.